Business Wire

AQM joins Eurofins | A stepping stone into Consumer Product Assurance

Share

Eurofins Consumer Products Testing (CPT) is proud to announce the acquisition of AQM. This acquisition provides a relevant, comprehensive range of product inspection and factory audit services in EMEA and Asia, significantly contributing to Eurofins’ continued growth plans and expansion into new fields and adjacent markets.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190702005690/en/

Eurofins acquires AQM expanding its excellence in inspection and audits, Corporate Social Responsibility and brand protection (Photo: Business Wire)

Eurofins acquires AQM expanding its excellence in inspection and audits, Corporate Social Responsibility and brand protection (Photo: Business Wire)

<<As a result of this operation, Eurofins strengthens its position as a leading company in the TIC sector worldwide, now offering the widest service portfolio covering the Global Supply Chain of retailers, brand owners and manufacturers across continents and consumer product industries>> explains Stéphane Barrau, VP Eurofins Consumer Product Testing.

Benoit Aubet , AQM Managing Director, comments: <<The acquisition will enable both Eurofins CPT and AQM to expand their service offerings within the consumer product testing industries, where both companies excel as a result of their respective expertise. AQM, historically focused on helping customers to deploy responsible sourcing while assuring product quality, now with the additional support of Eurofins CPT will continue to provide high level inspection and audit services with a wider scope and more extended geographic coverage.>>

The company will hereinafter be referred to as “Eurofins | AQM ”.

About AQM

Established in 2005 in France, and subsequently moving to Shanghai in 2007 followed by continuous expansion ever since, AQM has established a significant reputation for excellence in inspection and audits, Corporate Social Responsibility and brand protection, mostly in Asia (China, Cambodia, Vietnam, Myanmar, India, Bangladesh, Pakistan), but also in EMEA (Europe, Turkey, Tunisia, Morocco and Ethiopia).

AQM is accredited by ICS and amfori-BSCI, partnering with some of the world-class brands on their social and environmental responsibility programmes.

AQM employs 280 highly skilled staff, comprising over 30 social and environmental auditors and 200 specialised inspectors.

About Eurofins

Eurofins Scientific is an international group of laboratories headquartered in Luxembourg, providing testing and support services to the pharmaceutical, food, environmental, agroscience and consumer products industries, among others.

The Group is one of the international leaders in the provision of testing services with a network of more than 800 laboratories across 47 countries. Through research and development, in-licensing and acquisitions, the Group draws on the latest developments in every industry it serves, while helping corporations to deliver safe and compliant products through responsible and sustainable sourcing practices.

Contact information

Ludovic Coppin
Email: ludovic.coppin@aqm-hk.com

Email: international@eurofins.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Gilead Presents New Data on Biktarvy® for the Treatment of HIV in Women and in Virologically Suppressed Patients With Known Resistance22.7.2019 16:00:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) today presented findings from two Phase 3 trials – a trial demonstrating the effectiveness of switching to Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets, B/F/TAF) in women, and a trial evaluating the potential for the single tablet regimen to be an effective treatment option in virologically suppressed patients with known resistance to nucleo(s)tide or non-nucleo(s)tide reverse transcriptase inhibitors (NRTIs or NNRTIs). The use of Biktarvy in patients with known drug resistance is investigational. These data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City. “These data presented at IAS provide new information about the treatment of HIV among women and patients with known drug resistance,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences. “The studies further demonstrate the potential for Biktarvy to be an

IBC Celebrates Young Talent in the Industry22.7.2019 15:36:00 CESTPress release

The media, entertainment and technology industry is changing. Attitudes are shifting, the next generation is consuming content differently to any before them and diverse and exciting content is being created to meet that demand in innovative formats. Driving this change is a new wave of industry talent, honoured at IBC with the first IBC Young Pioneer Award. Recognising the brightest, newest talent in the industry, this award will go to someone who has made a real impact with their passion, ambition and commitment and is making an outstanding contribution to our industry. “What we were looking for in the shortlist was, most importantly, real talent, a stand-out individual making a real difference in the industry,” said David Levine, VP, Programming - Kids, Europe & Africa/UK & Ireland, The Walt Disney Co. Ltd and Chair of the Judging Panel. “But we were also looking for a lasting legacy, for the Young Pioneer to be a leader today and a media guru of the future.” The call for entries so

Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV22.7.2019 15:00:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) today presented the first clinical data in people living with HIV on GS-6207, an investigational, novel, selective, first-in-class inhibitor of HIV capsid function. The Phase 1b data demonstrate the first proof of concept that HIV capsid inhibition can lead to significant declines in viral load in vivo. In addition, Gilead presented preclinical data demonstrating that resistance to GS-6207 in vitro did not lead to resistance to other classes of drugs used in the treatment of HIV. These data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City. GS-6207 is an investigational long-acting antiretroviral agent that can be delivered subcutaneously. GS-6207 recently received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) as a potential therapy for heavily treatment-experienced people living with multi-drug resistant HIV. GS-6207 acts in a novel way compared with current

Pacific Drilling Appoints James W. Harris as Chief Financial Officer22.7.2019 13:42:00 CESTPress release

Pacific Drilling S.A. (NYSE: PACD), one of the world’s leading deepwater drilling contractors, today announced that Pacific Drilling’s Board has appointed James W. Harris to serve as the Company’s Senior Vice President and Chief Financial Officer. Mr. Harris replaces Mr. Johannes (John) P. Boots, who, as previously announced, mutually agreed with the Company to step down from his position to pursue other opportunities. Mr. Harris has more than 30 years of experience in the energy industry in a variety of financial leadership, strategic and business planning roles. He most recently served as Executive Vice President, Drilling & Subsea for Forum Energy Technologies, Inc., having previously served Forum as Chief Financial Officer for 12 years. Bernie Wolford, the Company’s Chief Executive Officer, stated, “We sincerely appreciate the many contributions that John has made during his nearly 10-year tenure with Pacific Drilling and we wish him all the best in his future endeavors.” “We are e

Moody’s Analytics Wins Credit Data Provider of the Year at Risk Technology Awards22.7.2019 11:00:00 CESTPress release

Moody’s Analytics, a global provider of financial intelligence, has won Credit Data Provider of the Year in the 2019 Risk Technology Awards. It’s one of six categories won, spanning finance, accounting, regulatory, and credit functions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005025/en/ The combined strength of Moody’s Analytics offerings earned the Credit Data Provider of the Year award. “We’re honored by this recognition,” said Jacob Grotta, Managing Director-Head of Risk & Finance Analytics. “Credit data challenges take many forms, and our capabilities are exemplified in a range of award-winning solutions.” Our Data Alliance is among the world’s largest and most comprehensive data consortia. Its global contributors share origination and performance data in C&I, CRE, project finance, asset finance, and other asset classes – and in return receive benchmarking across a host of metrics as well as detailed reports

U.N. Environment Programme Urged to Protect Nature and Humankind from Electromagnetic Fields (EMF)22.7.2019 11:00:00 CESTPress release

The Advisors to the International EMF Scientist Appeal, representing 248 scientists from 42 nations, have resubmitted The Appeal to the United Nations Environment Programme (UNEP) Executive Director, Inger Andersen, requesting the UNEP reassess the potential biological impacts of next generation 4G and 5G telecommunication technologies to plants, animals and humans. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005154/en/ Ronald L. Melnick, PhD, who led the design of the large $30 million NIH/NTP Animal Study, which showed Radio Frequency Radiation emitted by cell phones and wireless devices causes cancer, confirms that the previously held assumption the radiation cannot cause cancer, or other adverse health effects, is wrong. (Photo: Business Wire) There is particular urgency at this time as new antennas will be densely located throughout residential neighborhoods using much higher frequencies, with greater biologica